Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers

Journal of Bone and Mineral Research

Volumn 17, Issue 8, 2002, Pages 1478-1485

  Buclin, Thierry ^a   Rochat, Monica Cosma ^a   Burckhardt, Peter ^a   Azria, Moïse ^b   Attinger, Martine ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone resorption markers; Calcitonin; Healthy humans; Intestinal absorption; Oral administration

Indexed keywords

SALCATONIN; CALCITONIN; CALCIUM;

ADULT; ARTICLE; BIOAVAILABILITY; BONE DISEASE; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INTESTINE ABSORPTION; MALE; OSTEOPOROSIS; PAGET BONE DISEASE; POSTTRAUMATIC OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; BLOOD; HALF LIFE TIME; PHASE 1 CLINICAL TRIAL; URINE;

ADULT; BIOLOGICAL AVAILABILITY; CALCITONIN; CALCIUM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; MALE;

EID: 0036676004     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.8.1478     Document Type: Article

References (49)

1. Drugs used in the treatment of metabolic bone disease: Clinical pharmacology and therapeutic use
2. Twenty-five years of salmon calcitonin: From synthesis to therapeutic use
3. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
4. Comparative safety of bone remodeling agents with a focus on osteoporosis therapies
5. Paget's disease of the bone: Observations after cessation of long-term synthetic salmon calcitonin treatment
6. Regional oral absorption, hepatic first-pass effect, and non-linear disposition of salmon calcitonin in beagle dogs
7. Colonic absorption of human calcitonin in man
8. Intracolonic bioavailability of human calcitonin in man
9. Metabolism of salmon and porcine calcitonin: An explanation for the increased potency of salmon calcitonin
10. Effect of different doses of nasal salmon calcitonin on bone mass
11. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
12. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis
13. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis
14. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin
15. The effect of rectal and nasal administration of salmon calcitonin in normal subjects
16. Acute effects of nasal salmon calcitonin on calcium and bone metabolism
17. Oral delivery of salmon calcitonin
18. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue
19. Transmucosal delivery systems for calcitonin: A review
20. Design of nanoparticles composed of graft copolymers for oral peptide delivery
21. Sustained release of salmon calcitonin in vivo from lactide-glycolide copolymer depots
22. Intestinal delivery of calcitonin in pig
23. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: In vitro-in vivo evaluation
24. Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs
25. Cortecs shares hit as drug for osteoporosis flops
26. The development of delivery agents that facilitate the oral absorption of macromolecular drugs
27. A mechanistic analysis of carrier-mediated oral delivery of protein therapeutics
28. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin
29. Pharmacokinetic study with synthetic salmon calcitonin (Sandoz)
30. Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man
31. Compared kinetics of salmon and human radioiodinated calcitonins in man
32. Comparative pharmacokinetics of calcitonins
33. Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose
34. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals
35. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption
36. Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers
37. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment
38. Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover
39. Acute effects of calcitonin on osteoclasts in man
40. + chez l'homme
41. Renal effects of calcitonin and parathyroid extract in man
42. Renal effects of calcitonin
43. Renal effects of salmon calcitonin in man
44. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study
45. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
46. Osteoporosis prevention, diagnosis, and therapy